-
Media ReleaseFDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media ReleaseNew analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-
Media ReleaseNovartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
-
Media ReleaseNovartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
-
Media ReleaseNovartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
-
Media ReleaseNEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media ReleaseMultimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media ReleaseNovartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media ReleaseNovartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media ReleaseLeeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media ReleaseNovartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media ReleaseNovartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community